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Abstract 
 
Background: Ban Huang oral liquid was developed as a veterinary compound preparation by the Lanzhou Institute of 
Husbandry and Pharmaceutical Sciences of the Chinese Academy of Agricultural Sciences (CAAS). The purpose of 
this study was to determine whether the oral liquid preparation of traditional Chinese medicine, Ban Huang, is safe and 
effective for treating respiratory diseases in cattle.  
Materials and Methods: Acute oral toxicity experiments were conducted in Wistar rats and Kunming mice via oral 
administration. The minimum inhibitory concentration of the drug against Mycoplasma bovis in vitro with the double 
dilution method was 500 mg/mL, indicating good sensitivity. The results of laboratory pathogen testing, analysis of 
clinical symptoms, and analysis of pathological anatomy were combined to diagnose bovine respiratory diseases in 147 
Simmental cattle caused by mixed infections of M. bovis, bovine respiratory syncytial virus, bovine parainfluenza virus 
type 3, and Mannheimia haemolytica. These cattle were randomly divided into three groups: drug treatment group 1 
(treated via Tilmicosin injection), drug treatment group 2 (treated with Shuang Huang Lian oral liquid combined with 
Tilmicosin injection), and drug treatment group 3 (treated with Ban Huang oral liquid combined with Tilmicosin 
injection). Treatment effects were observed within 7 days.  
Results: The results showed no toxicity and a maximum tolerated dose greater than 20 g/kg BW. For the 87 cattle in 
drug-treatment group, the cure rate was 90.80%, whereas the response rate was 94.25%. The cure rate of drug treatment 
group was increased by 14.13% in comparison with that of drug control group 1 and by 7.47% in comparison with that 
of drug control group 2 (both P < 0.05).  
Conclusion: This study demonstrates that Ban Huang oral liquid is a safe and effective treatment for bovine respiratory 
diseases, especially for mixed infection caused by M. bovis, bacteria, and viruses. 
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Introduction 
 
Bovine respiratory diseases threaten the healthy development of the cattle breeding industry throughout the world. 
Ranking second only to severe infectious diseases in incidence and mortality, respiratory disease is the most significant 
and widespread cause of economic loss in the beef cattle industry (Ellis, 2001). The Chinese Ministry of Agriculture 
has organized relevant experts to conduct in-depth investigations on recent prevalent bovine respiratory diseases in 
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China. By combining laboratory pathogen testing with analysis of clinical symptoms and epidemiological surveys, it 
was found that the main pathogen inducing respiratory diseases in cattle in China was Mycoplasma bovis, followed by 
Pasteurella multocida, bovine respiratory syncytial virus, and bovine parainfluenza virus type 3 (BPIV-3), all of which 
can join in mixed infections. The M. bovis pathogen is a particularly serious concern for cattle breeders because of the 
relative difficulty in diagnosing respiratory disease caused by the mycoplasma, the lack of an effective antibiotic 
against it, and its persistence and transmissibility (Caswell, 2007; Fox et al., 2005). The first report on the connection 
between M. bovis and bovine respiratory diseases was published in 1976 (Nicholas and Ayling, 2003). Although M. 
bovis can act as a primary pathogen, many cases of disease showed co-infection with other bacteria or viruses (Caswell 
et al., 2010). 
The worldwide spread of M. bovis has recently gained momentum (Cai et al., 2005; van der Burgt et al., 2008; 
Dyer et al., 2008), causing significant economic losses for the cattle industry. For example, the annual economic loss in 
the United States due to bovine respiratory diseases reached 500 million US dollars (Wilkinson, 2009; Miles, 2009). In 
Holland, Laak et al. found that the rate of M. bovis infection was greater than 20% at a cattle-fattening farm, where few 
cattle were considered completely healthy (Buchvarova and Vesselinova, 1989). In Switzerland, bovine respiratory 
diseases caused by M. bovis account for more than 50% of all respiratory diseases and reduce the growth rate of 
latently infected herds by 8% (Poumarat et al., 2001). Nearly all outbreaks of M. bovis infection in China are related to 
transport, with most cattle showing signs of onset approximately one week after arriving at their destination (Shi et al., 
2008). To date, there is no effective vaccine to prevent M. bovis infection (Mulongo et al., 2013). Currently, bovine 
respiratory disease associated with M. bovis infection is treated primarily with antibiotics. However, antibiotic therapy 
is rarely effective, the prevalence of antimicrobial resistance is reportedly increasing (Gautier-Bouchardon et al., 2014; 
Li et al., 2011), and antibiotic residue in cattle poses a serious threat to food safety and public health. 
Traditional Chinese medicine (TCM) has played an important role in health protection and disease control for 
millennia. The therapeutic efficacy of TCM is based on the combined actions of constituents of phytochemical 
mixtures. TCM is utilized in many countries and districts, and the global market for herbal medicine is growing 
annually. TCM is widely accepted in Asian countries, and its popularity is also increasing in western countries. For 
example, the publication “Guidance for Industry: Botanical Drug Products” produced by the US Food and Drug 
Administration signals basic acceptance of TCM in western countries (Xu, 2008). TCM is useful in the prevention and 
control of bacterial infections (Wei et al., 2008). Huang et al. (Huang et al., 2005) generated a TCM preparation using 
the extracts of ten medicinal herbs (including Chrysanthemum indicum, Andrographis paniculata, Radix bupleuri, 
Houttuynia cordata, and Folium isatidis) and tested its protective effects against avian influenza virus H9N2, 
Newcastle disease virus, infectious bronchitis virus, and Mycoplasma gallisepticum using challenge experiments, 
demonstrating that the TCM preparation effectively controlled respiratory disease in poultry caused by these four 
pathogens. Qingkailing Injection was developed based on the ingredients in the Cow-Bezoar Bolus for Resurrection, 
the primary TCM preparation used to treat febrile and epidemic diseases. Qingkailing Injection is an outstanding 
representative of heat-clearing and detoxifying Chinese patent medicines that promotes regaining consciousness and 
has antibacterial, antiviral, antipyretic, and analgesic actions. Qingkailing Injection contributed greatly to efforts to 
control SARS, influenza A virus subtype H1N1, human avian influenza, and hand-foot-mouth disease (Guo, 2015; Lu 
et al., 2006). Zhang et al. (Zhang et al., 2007) controlled nephropathogenic infectious bronchitis in broiler chickens by 
adding veterinary Hushensuxiaosan Decoction (Shaanxi ShengAo Animal Pharmaceutical Co., Ltd.) and 
Shenzhongbaidu Decoction (Jiangxi Zhongcheng Medicine Group Co., Ltd.) to a centralized drinking water system. 
Studies have demonstrated that Chinese medicinal herbs can fully activate the immune system to enhance immunity. 
Chinese medicinal herbs have the advantages of easy accessibility, low cost, low toxicity, and drug tolerance (Huo and 
Li, 2002; Shen et al., 2004; Zhang et al., 1998). 
The goal of this study was to prepare a compounded Chinese medicinal prescription to treat bovine respiratory 
diseases, especially pneumonia, caused by mycoplasmic infections. TCM drugs can be used to reduce antibiotic 
tolerance and residue in cattle. Ban Huang oral liquid was developed as a veterinary compound preparation by the 
Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences (CAAS). 
The main ingredients of Ban Huang oral liquid included Isatidis Radix, Coptidis Rhizoma, Lonicerae Joponicae Flos, 
Scutellariae Radix, Anemarrhenae Rhizoma, Glycyrrhizae Radix et Rhizoma.Isatidis Radix, Coptidis Rhizoma, 
Lonicerae Joponicae Flos, and Scutellariae Radix, which have heat-clearing and detoxifying properties, as well as 
blood-cooling, throat-easing, and antibacterial actions (Li, 2005; Chinese Pharmacopoeia Commission, 2010). 
Anemarrhenae Rhizoma has heat-clearing, fire-purging, yin-nourishing, dryness-moistening, blood-cooling, 
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throat-easing, and anti-inflammatory actions (Chinese Pharmacopoeia Commission, 2010). Glycyrrhizae Radix et 
Rhizoma has the effects of invigorating the spleen, replenishing qi, heat-clearing, detoxifying, and expelling phlegm to 
arrest coughing; therefore, it is used for the coordination of various drugs (Chinese Pharmacopoeia Commission, 2010).  
The combined use of the ingredients in Ban Huang oral liquid can achieve the effects of heat-clearing, 
detoxifying, removing dampness and swelling, arresting bleeding, and easing throat soreness; indeed, these ingredients 
have been applied to treat many febrile diseases. Coptidis Rhizoma and Scutellariae Radix, the main ingredients in Ban 
Huang oral liquid intended to treat respiratory diseases, have heat-clearing, detoxifying, and antibacterial actions. 
Berberine hydrochloride and baicalin were chosen as indices for quality control of Coptidis Rhizoma and Scutellariae 
Radix, respectively, because the detection methods for these compounds are stable and reliable. 
Shuanghuanglian oral liquid (composed of Lonicerae Joponicae Flos, Scutellariae Radix, and Forsythiae Fructus) 
(Jia, 2013) was compared with Ban Huang oral liquid because Shuanghuanglian oral liquid the former has 
heat-clearing, detoxifying, and antibacterial actions. It is widely used in the clinical mainly for to treat respiratory 
infections, including pneumonia., etc. (Jia, 2013; Zhang, 2010). Through the acute toxicity experiments and clinical 
pharmacodynamic studies presented here, this study demonstrates that Ban Huang oral liquid is a safe and effective 
treatment for bovine respiratory diseases, especially mixed infection caused by M. bovis, bacteria, and viruses. 
 
Materials and Methods  
Materials 
  
Isatidis Radix, Coptidis Rhizoma, Lonicerae Joponicae Flos, Scutellariae Radix, Sophorae Tonkinensis Radix et 
Rhizoma, Arctii Fructus, Platycodonis Radix, Anemarrhenae Rhizoma, and Glycyrrhizae Radix et Rhizoma were 
purchased from the Lanzhou HuiRenTang Pharmacy and certified by GSP. Ban Huang oral liquid (1 g/mL crude drug, 
batch no. 20090615) was provided by the Lanzhou Institute of Husbandry and Pharmaceutical Sciences, CAAS.  
Shuanghuanglian oral liquid (1 g/mL crude drug, batch no. 2006 020115030) was provided by Tianjin 
Zhongsheng TiaoZhan Bioengineering Co., Ltd. Tilmicosin injection (3 g/10mL, batch no. 20090717) was provided by 
Sichuan Zhibang Biological Technology Co., Ltd. Baicalin (batch no. 110715-200815) and berberine hydrochloride 
(batch No. 110713-200911) were provided by the National Institute for the Control of Pharmaceutical and Biological 
Products and used as standards. Chromatographically pure acetonitrile and methanol were obtained from Fisher 
Company (USA). Industrial grade ethanol, 95% ethanol, potassium dihydrogen phosphate, sodium dodecyl sulfate, 
sodium benzoate, phosphoric acid, agar, thallium acetate, penicillin, sodium hydroxide, and phenolsulfonphthalein 
were obtained from Sinopharm Group Co. Ltd. PPLO broth base was obtained from BD Co. (USA). Glucose and 
β-nicotinamide adenine dinucleotide were obtained from Sangon Biotech (Shanghai) Co., Ltd. Fetal bovine serum was 
obtained from Zhejiang Tianhang Biological Technology Co., Ltd. M. bovis strain gs-1 was isolated, identified, and 
preserved by the Lanzhou Institute of Husbandry and Pharmaceutical Sciences, CAAS. 
 
Equipment 
 
A Waters 2695 HPLC System coupled with a UV detector (Waters Co., USA), an AEL-1600 electronic balance 
(Shimadzu, Japan), and a Millipore water purification system (USA) were used in these experiments. 
 
Ethics statement 
 
The protocol was approved by the Ethics Committee of Animal Experiments of Lanzhou Institute of Husbandry 
and Pharmaceutical Sciences of CAAS, which was commissioned by The International Cooperation Committee of 
Animal Welfare (ICCAW) affiliated with the China Association for the Promotion of International Agricultural 
Cooperation (CAPIAC). The mouse toxicity study and cattle treatment procedures were subject to the ethical oversight 
of the Ethics Committee of Animal Experiments of Lanzhou Institute of Husbandry and Pharmaceutical Sciences of 
CAAS and implemented in accordance with the technical guidelines for clinical trials for veterinary TCM and natural 
drugs. 
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Study protocol 
 
This study used six batches of Ban Huang oral liquid prepared with stable and quality controllable processes. 
Quality control indices were detected using high performance liquid chromatography (HPLC). Inter-batch differences 
were tested; relative standard deviation (RSD) was required to be less than 5%. Acute oral toxicity experiments were 
conducted in rats to evaluate the clinical safety of the drug. The sensitivity of M. bovis to the drug was determined 
according to the guidelines for therapeutic drug trials in the Collections of Technical Requirements for Veterinary Drug 
Trials (Ministry of Agriculture, 2001). The method for diagnosing bovine diseases was established along with the 
criteria for evaluating the treatment effect. The mortality, cure rate, and response rate were calculated after Ban Huang 
oral liquid was administered. The results were compared with those obtained using Shuang Hang Lian oral liquid.  
Intergroup differences were statistically tested, and the efficacy of Ban Huang oral liquid for treating bovine 
respiratory infectious diseases was evaluated. 
 
Preparation of Ban Huang oral liquid  
 
The optimal soaking time was determined based on the water absorption of the drug using the concentration of the 
quality control ingredients as indicators. The water extraction process was optimized using L9 (34) orthogonal array 
testing. An analysis of variance was performed to determine and verify the process. The concentration and relative 
density were measured, and the clarity and transport rate of the main quality control ingredients were used as indicators 
to characterize the alcohol precipitation method. 
 
Concentration determination for quality control 
 
An HPLC-UV method was used to determine the concentrations of baicalin and berberine hydrochloride in Ban 
Huang oral liquid. The baicalin reference and berberine hydrochloride reference were accurately weighed, after which 
reference solutions of 5 mg/mL and 10 mg/mL, respectively, were generated using methanol. Six batches of Ban Huang 
oral liquid (1 mL each) were individually weighed and placed into separate 50-mL flasks. The solution was diluted to 
50 mL with methanol and mixed well. A C18 HPLC column was used with an aqueous solution of methanol and 0.1% 
phosphoric acid (50:50) as the mobile phase. Baicalin was detected at a wavelength of 274 nm (1.0 mL/min flow rate, 
10 µL sample size). The number of theoretical plates was calculated using the baicalin peak and was required to be 
greater than 2,500. Octadecyl silane chemically bonded to silica was used as filler, and an aqueous solution of 
acetonitrile and potassium dihydrogen phosphate (47:53, v/v, 3.2 g potassium dihydrogen phosphate and 1.6 g sodium 
dodecyl sulfate in every 1 L of water) was used as the mobile phase. The concentration of berberine hydrochloride was 
detected at a wavelength of 347 nm (10 µL sample size). The number of theoretical plates was calculated using the 
berberine hydrochloride peak and was required to be greater than 5,000. 
 
Drug safety evaluation in acute oral toxicity experiments in rats and mice 
 
The protocol followed the guidelines recommended in the Guidance of Veterinary Drugs for Technical Study, 
2006–2011 (Ministry of Agriculture, 2012). Sixty Kunming mice (30 female and 30 male) weighing 18–22 g (license 
no. scxk [Gansu] 2012-0075) and sixty Wistar rats (30 female and 30 male) weighing 200–250 g (license No. scxk 
[Gansu] 2012-0075) were used in the experiments. All rodents were purchased from the Medical School of Lanzhou 
University. The rats and mice were randomly divided into six groups (n = 10 per group, 5 males and 5 females) based 
on body weight. Intragastric irrigation was performed once daily. For control mice, normal saline was gavaged at a 
dose of 10 g/kg BW. Five experimental groups were gavaged at doses of 5, 10, 15, 18, or 20 g/kg BW (one dose per 
group). The mental state, behavior, and food intake of the mice were observed for 14 consecutive days. 
 
Susceptibility testing 
 
A PPLO broth base was supplemented with fetal bovine serum, 25% yeast leachate, 10% glucose, 10% arginine, 
0.4% phenolsulfonphthalein, 1% thallium acetate, and 1% penicillin. The M. bovis strain was aspirated using a 
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micropipettor, inoculated into the PPLO broth, and cultured at 37 °C in a 5% CO2 incubator for 48–72 h. The PPLO 
broth was added to 12 sterile screw-cap test tubes (1.8 mL each) using the double dilution method and cultured at 37 °C 
in a 5% CO2 incubator for 48–72 h. The color change of the culture media was observed, and the color-changing unit 
(CCU) was determined as the concentration of the highest dilution that changed the color of the media. For example, if 
the 5th tube in the dilution series was the highest dilution to show a color change, then the CCU was 1 × 10-5/mL. 
The MIC of Ban Huang oral liquid was determined using the microdilution method in accordance with the 
guidelines of the Clinical and Laboratory Standards Institute (CLSI/NCCLS, 2003). The optimal concentration of M. 
bovis in the drug sensitivity test was 1 × 10-3 to 1 × 10-4 CCU per 0.2 mL; a concentration of 1 × 10-4 CCU was used for 
MIC determination. The MIC was defined as the drug concentration in the tube before the first color change after 
48–72 h of incubation at 37 °C. The experiment was repeated for confirmation when no tubes showed a color change 
after 3–6 d. 
 
Study animals 
 
A total of 147 Simmental cattle (aged 6–12 months) affected by respiratory diseases were reared in two-row barns 
at Fucheng Beef Cattle Farm in Sanhe City (Hebei Province) and Wanhe Beef Cattle Farm in Zhangye City (Gansu 
Province). All cattle were in the stage of disease onset and showed the following symptoms: increased body 
temperature (approximately 41°C), continued fever, poor appetite, coarse and disordered hair, emaciation, cough, 
shortness of breath, diarrhea, and hemafecia. We had the permission of the cattle farm owners to perform the treatment 
study. 
 
 
 
Clinical diagnosis:  
 
Diagnosis was made by combining the results of the clinical observations of symptoms with those of pathological 
anatomy analysis and laboratory pathogen testing. Laboratory pathogen testing was conducted as follows: a TaqVet 
Triplex Pasteurella multocida/Mannheimia haemolytica fluorescence qPCR kit and TaqVet Mycoplasma bovis 
fluorescence qPCR kits were used to examine mucus from the nasal cavities of affected cattle. DNA extraction was 
performed using a QIAamp DNA mini kit (QIAGEN, 51304). Bovine respiratory syncytial virus and BPIV-3 were 
detected using the TaqVet Triplex bRSV & PI3 kit with mucus from the trachea and bronchus. A QIAGEN kit 
(QIAamp Viral RNA Mini Kit: 52904 or 52906) was used for RNA purification and identification. Detections were 
conducted before and after treatments. 
 
Efficacy evaluation 
 
Cattle were considered cured when all clinical symptoms of respiratory diseases were absent, appetite and mental 
state were restored to normal, and laboratory pathogen tests of respiratory secretions were negative. Cattle were 
considered responsive when clinical symptoms were markedly alleviated, with restoration of appetite and mental state. 
The treatment was considered ineffective when clinical symptoms of respiratory diseases were not alleviated or were 
aggravated, appetite declined or was completely lost, mental state was poor, and laboratory pathogen tests of 
respiratory secretions were positive. 
 
Treatment 
 
The 147 affected cattle (clinically diagnosed and experimentally confirmed) were randomly divided into three 
groups. Drug control group 1 was comprised of 30 cattle that were treated with Tilmicosin injection at a dose of 10mg/ 
kg body weight (BW) by subcutaneous injection once daily for 1 d. Drug control group 2 was comprised of 30 cattle 
that were treated with Shuang Hang Lian oral liquid at a dose of 0.4 mL/kg BW twice daily for 7 d, followed by 
combined treatment with Shuang Hang Lian oral liquid (0.4 mL/kg BW) and Tilmicosin injection (10 mg/kg BW) by 
subcutaneous injection for 1 d. The experimental drug treatment group (n = 87 cattle) was treated with Ban Huang oral 
liquid (0.4 mL/kg BW) twice daily for 7 d, followed by combined treatment with Ban Huang oral liquid (0.4 mL/kg 
BW) and Tilmicosin injection (10 mg/kg BW) by subcutaneous injection once daily for 1 d.  
 
Results 
Preparation of Ban Huang oral liquid 
 
The optimal preparation process for Ban Huang oral liquid was determined through preliminary trials. Isatidis 
Radix, Coptidis Rhizoma, Lonicerae Joponicae Flos, Scutellariae Radix, Sophorae Tonkinensis Radix et Rhizoma, 
Arctii Fructus, Platycodonis Radix, Anemarrhenae Rhizoma, and Glycyrrhizae Radix et Rhizoma were soaked in water 
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for 12 h and boiled twice for 1 h each time. For the first boiling, 7 times the volume of water was added, and for the 
second boiling, 5 times the volume of water was added. The resulting liquid was combined and filtered, after which the 
filtrate was condensed to a relative density of 1.18–1.25 (25 °C). Next, ethanol was slowly added until the proportion 
reached 60%; this solution was mixed well and left to stand for 24 h. The supernatant was collected after filtration to 
recover ethanol until there was no ethanol aroma left in the remaining filtrate. Next, ethanol was added again until the 
proportion reached 75%, after which the solution was mixed and left to stand for 24 h. The supernatant was collected 
by filtration and ethanol was recovered until no ethanol aroma remained. Sodium benzoate (3 g) was added to the 
resulting solution, which was diluted with water to a volume of 1000 mL, mixed well, sterilized by boiling, and bottled 
under sterilized conditions. 
 
Concentration determination 
 
The prescription consisted of the nine herbs listed above. Berberine hydrochloride and baicalin were detected 
using HPLC to evaluate the preparation process and perform quality control of active ingredients Coptidis Rhizoma and 
Scutellariae Radix, respectively. The results of these assays demonstrated that the RSD values for baicalin and 
berberine hydrochloride in all six batches of Ban Huang oral liquid were less than 5%, indicating good reliability and 
stability of the preparation process (Tables 1, 2 and Fig 1, 2). 
 
Table 1: Baicalin concentration in Ban Huang oral liquid. 
Batch no. Mean content ± SD (μg/mL) RSD (%) 
20100122 1032.55 ± 5.37  
20100123 1103.14 ± 2.55  
4.37 20100124 983.18 ± 3.18 
20090614 1036.55 ± 6.73 
20090615 1068.97 ± 3.21 
20090616 1100.72 ± 6.42  
 
 
Table 2: HPLC chromatograms of berberine hydrochloride in Ban Huang oral liquid. 
 
 
Batch no. Mean content ± SD (μg/mL) RSD (%) 
20100122 33.56 ± 1.12 
 
 
4.05 
20100123 30.17 ± 2.03 
20100124 32.67 ± 0.98 
20090614 32.11 ± 1.31 
20090615 31.98 ± 0.83 
20090616 33.80 ± 1.24 
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Figure1: Representative HPLC chromatograms showing baicalin peaks in Ban Huang oral liquid. (A) is the 
chromatogram of the reference substance, and (B) is the chromatogram of the sample. 
  
Figure 2: Representative HPLC chromatograms of berberine hydrochloride in Ban Huang oral liquid. (A) is the 
chromatogram of the reference substance, and (B) is the chromatogram of the sample. 
 
 
 
 
 
Safety evaluation 
 
Acute oral toxicity experiments were conducted in rats and mice (n = 10 of each in control and each treatment 
group). No rodents died following treatment with Ban Huang oral liquid (5, 10, 15, 18, or 20 mg/kg BW) for 14 days. 
During the treatment, rats and mice showed a normal mental state, normal food intake, and normal water intake, 
without any adverse reactions. The maximum tolerated dose (LD0) of Ban Huang oral liquid in rodents was greater than 
20 g/kg BW; thus, the median lethal dose (LD50) is greater than this value. Therefore, according to the standards for 
toxicological classification of drugs, Ban Huang oral liquid was considered nontoxic. 
No fatalities occurred in any of the groups of rats or mice, and no animal was sacrificed during this study. 
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MIC determination 
 
The M. bovis strain was cultured in an incubator for 48 h to 72 h until the color of the culture medium turned 
translucent yellow. Proliferating M. bovis cells were subjected to 10-fold serial dilution and cultured at 37 °C until the 
media did not change color after 48–72 h. The results demonstrated that the endpoint dilution was 1 × 10-7. Thus, the 
CCU of M. Bovis strain gs-1 was 1 × 107 CCU/mL. The MIC of Hainosankyuto was greater than 500 mg/mL (Fig. 3). 
These results indicate that Ban Huang oral liquid significantly inhibited visible growth of M. bovis. 
  
Figure 3: Inhibitory effect of Ban Huang oral liquid on the growth of M. bovis in vitro. The X-axis values (1–6) 
represent different concentrations of drug (1000 mg/mL, 500 mg/mL, 250 mg/mL, 125 mg/mL, 62.5 mg/mL, 31.25 
mg/mL); 1 and 2, color changed; 3–6, no color changes; the lowest concentration of drug that inhibited visible growth 
of M. bovis was 500 mg/mL. 
 
Diagnosis 
 
The cattle showed clinical symptoms consistent with those of bovine respiratory disease. During early onset of 
respiratory disease, severely affected cattle stopped eating, while their body temperature increased to 41.3 ± 0.2 °C. 
The affected cattle had difficulty breathing, groaned, and presented with abdominal breathing and tenderness upon rib 
pressing. The cattle refused to crouch and demonstrated pain on coughing, which was aggravated early in the morning 
and during the night. Clear or purulent nasal discharge was observed with weakened or no vesicular breath sounds 
during lung auscultation. Death rattles and pleural friction sounds were heard. The stool was loose and contained blood 
in secondary diarrhea. Lameness and joint abscesses were observed along with secondary arthritis. Few severely 
affected cattle showed a poor mental state, disordered and lusterless hair, emaciation, or dry cough. In the late stage of 
infection, the affected cattle were severely anorectic and lay down; they exhibited shortness of breath or weak breathing 
and eventually died of respiratory failure. 
As shown in Figure 4, the results of laboratory pathogen testing indicated that cattle infection was mainly caused 
by M. bovis. These results also demonstrated that Ban Huang oral liquid had the strongest inhibitory effect on M. bovis 
and the weakest inhibitory effect on BPIV-3, among the tested pathogens. After assessing the pathogen testing results 
with clinical symptoms, 147 cattle were diagnosed as having bovine respiratory diseases caused by M. bovis, bovine 
respiratory syncytial virus, M. haemolytica, and BPIV-3. 
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Figure 4: Results of laboratory pathogen testing in 147 cattle. 1: Mannheimia haemolytica; 2: Mycoplasma bovis; 3: 
bovine respiratory syncytial virus; 4: BPIV-3. Because Pasteurella multocida was not detected before or after drug 
treatment, results for this organism are not shown. *, significant difference. 
 
Treatment outcome 
 
After drug treatment for 7 days, clinical symptoms completely disappeared in some cattle, in which the results of 
laboratory testing for pathogens were negative; moreover, these cattle showed normal body temperature, uniform 
breathing without any coughing, and no death rattles or diarrhea. These cattle had a good mental state, glossy hair, and 
normal appetite; thus, they were considered cured. Some of the cattle tested positive for pathogens, but their symptoms 
were alleviated; these animals were considered responsive. Other animals showed no alleviation or even aggravation of 
symptoms; treatment was considered ineffective in these animals.  
Variation in the body temperature of drug control group 1, drug control group 2, and the experimental drug 
treatment group over 7 days of treatment is shown in Fig. 5. The average temperature of drug control group 1 declined 
from 41.1 °C to 38.9 °C, a 1.2 °C reduction. The average temperature of drug control group 2 declined from 40.8 °C to 
38.8 °C, a 2.0 °C reduction. For the experimental drug treatment group, the average body temperature declined from 
41.1 °C to 38.6 °C, a 2.5 °C reduction. These results show that there was a significant decline in the body temperature 
of each group within 24 h after drug administration. Moreover, there was a significant difference in the decline in the 
body temperature of the experimental drug treatment group in comparison with that of drug control group 1 and drug 
control group 2 (P < 0. 05). 
After 7 days of treatment, 79 animals in the experimental drug treatment group were cured (90.80% cure rate), 
whereas 82 were responsive and 4 did not respond to the treatment, which was deemed ineffective. In drug control 
group 1, 23 animals were cured (76.67% cure rate) and 26 were responsive; the treatment was ineffective in 4 animals. 
In drug control group 2, 25 animals (83.33% cure rate) and 27 were responsive; the treatment was ineffective in 3 
animals. These results are shown in Figure 6. No animal died in the experimental drug group, in which the cure rate 
was increased by 14.13% compared with that of drug control group 1 and by 7.47% compared with that of drug control 
group 2 (both P < 0.05). Thus, Ban Huang oral liquid was effective against bovine respiratory disease, superior to 
Shuang Hang Lian oral liquid and Tilmicosin alone, and nontoxic. 
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Figure 5: Variation in the body temperature of drug control group 1, drug control group 2, and the experimental drug 
treatment group over 7 days of treatment. The average temperature of drug control group 1 declined from 41.1 °C to 
38.9 °C, a 1.2 °C reduction. The average temperature of drug control group 2 declined from 40.8 °C to 38.8 °C, a 2.0 
°C reduction. For the experimental drug treatment group, the average body temperature dropped from 41.1 °C to 38.6 
°C, a 2.5 °C reduction. *, significant difference. 
 
Figure 6: Inhibitory effect of Ban Huang oral liquid against bovine respiratory diseases caused by a mixed infection. 
The number of ineffective cases was defined as the number of cattle showing no alleviation of symptoms at the end of 
treatment. Cure rate (%) = (number cured/number affected) × 100. Response rate (%) = (number cured + number of 
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responsive cattle)/number affected × 100. No response rate (%) = (number of ineffective cattle/number affected) × 100. 
*, significant difference. 
 
Discussion and Conclusions  
 
Berberine hydrochloride and baicalin were chosen as quality control indices. Other components were analyzed 
using thin layer chromatography (results not shown). The concentrations of berberine hydrochloride and baicalin in the 
drug were measured using HPLC. In batch production, the concentrations of berberine hydrochloride and baicalin 
should be the top priorities of quality control testing if the sources of crude drug are not uniform. The application of the 
chromatographic fingerprint technique to the evaluation of the quality homogeneity and stability of crude medicinal 
herbs, semi-finished drugs, and finished drug products is currently under study. 
M. bovis infection impairs immunity in the respiratory mucosa of cattle. Most bovine respiratory diseases occur in 
calves during long-distance transportation. Immunity greatly declines after long-distance transportation, when the cattle 
are likely to show stress responses and be infected by M. bovis and other pathogens. Chinese medicinal herbs destroy 
the cell membranes and cell walls of pathogens, inhibiting synthesis and expression of proteins. Moreover, TCM herbs 
may also act directly on DNA structure and interfere with its normal function (Tang et al., 2005), thereby affecting 
microbial growth and proliferation (Chen et al., 1994), eventually leading to pathogen death (Snyder and Gillies, 2002; 
Mittra et al., 2000). In this study, the ability of Ban Huang oral liquid to inhibit the growth of M. bovis was confirmed 
in vitro. However, the effectiveness of the drug in vivo requires further experimental verification. 
Simon Frantz, the chief editor of a column on drug discovery in the journal Nature, said that researchers should “forget 
drugs carefully designed to hit one particular molecule—a better way of treating some complex diseases may be to aim 
for several targets at once” (Lee et al., 2005). Both humans and animals are complex organisms, which need to be 
controlled by complex drugs. TCM uses a combination of active components to reach this goal (Kitano, 2007), 
triggering the immune system and enhancing immunity (Huo and Li, 2002; Shen et al., 2004; Zhang et al., 1998), and 
thus preventing and treating disease. 
Ban Huang oral liquid is easy to prepare, while its quality control methodology is simple. The quality and stability 
of Ban Huang oral liquid can meet the demands of mass production. Thus, bovine respiratory diseases caused by a 
mixed infection can be effectively controlled using Ban Huang oral liquid. As a Chinese medicinal product, Ban Huang 
oral liquid has no toxicity and causes no drug residue or drug resistance problems. Ban Huang oral liquid has great 
potential for use as a new veterinary drug for respiratory diseases; in addition to therapeutic effects, this preparation has 
preventive effects against respiratory diseases in livestock and poultry. Because of its good efficacy and safety, Ban 
Huang oral liquid warrants extensive promotion as a veterinary drug. Moreover, Ban Huang oral liquid provides 
inspiration for system-oriented drug design and efforts aimed at discovering new drugs to treat and prevent bovine 
respiratory diseases. Because bovine respiratory diseases have a high rate of incidence and cause significant harm, 
drug-based prevention is only part of the treatment strategy. All necessary control and prevention measures should be 
adopted to ensure the healthy development of the animal farming industry by optimizing the breeding and rearing 
environment, as well as transportation, vaccination, safety isolation, and medication methods. 
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